Kenshi Suzuki

14PUBLICATIONS
54CO-AUTHORS
Molecular medicineNanomedicineCancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsPredictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (14)

|Sep 16, 2026
Japanese subgroup analysis of AQUILA trial: daratumumab vs active monitoring in high-risk smoldering multiple myeloma.

|Jun 03, 2026
Daratumumab in transplant-ineligible or -deferred newly diagnosed multiple myeloma: minimal residual disease in CEPHEUS.

|May 12, 2026
Daratumumab-bortezomib-cyclophosphamide-dexamethasone for newly diagnosed amyloidosis: ANDROMEDA final survival analysis.

|Mar 27, 2026
Daratumumab plus VRd in Japanese transplant-ineligible/deferred NDMM patients: Japanese subgroup of the CEPHEUS trial.

Kenshi Suzuki, Morio Matsumoto, Hiroyuki Takamatsu

|Dec 04, 2023
Daratumumab for patients with myeloma with early or late relapse after initial therapy: subgroup analysis of CASTOR and POLLUX.

Andrew Spencer, Philippe Moreau, Maria-Victoria Mateos

|Nov 29, 2023
Late versus early response and depth of response are associated with improved outcomes in patients with newly diagnosed multiple myeloma enrolled in the TOURMALINE-MM2 trial.

Paul G Richardson, Thierry Facon, Christopher P Venner

Pageof 3

Frequent Collaborators

3 joint publications

Vania Hungria

3 joint publications

Nizar J Bahlis

2 joint publications

Angelo Maiolino

2 joint publications

Sung-Soo Yoon